Antibiotic Indications: Definition Of “Significant” Remains In FDA’s Hands After Vancocin Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
D.C. District Court Judge denies ViroPharma’s request for a preliminary injunction to require FDA to withdraw approval of three ANDAs, says company is unlikely to prevail in its suit challenging agency’s actions.
You may also be interested in...
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.